|  |  | 

India Top Headlines

Chinese vaccine shows results in early trials, shows promise | India News


NEW DELHI: Results from the first phase 1/2 randomized clinical trials of a Chinese Covid-19 vaccine, CoronaVac, have shown it to be safe and elicit a good antibody response in adults ages 18 to 59, adding to to the list of vaccines being tested that have been shown to be safe.
The candidate vaccine, developed by Sinovac Life Sciences in Beijing, contains an inactivated SARS-CoV2 virus. The results of the trial have been published in the journal ‘Lancet Infectious Diseases’.
However, the efficacy of the vaccine has not yet been tested in the next phases of the trial. While the average levels of neutralizing antibodies induced by CoronaVac were lower than the levels seen in people who had Covid-19, the researchers still believe that the formulation could provide sufficient protection against the virus based on their experience with other vaccines and data from studies. of animal models.
The findings show that the candidate vaccine could induce an antibody response in participants within 28 days of the first immunization, by administering two doses 14 days apart. The researchers found that most of the adverse reactions were mild, with pain at the injection site being the most common symptom, which is in agreement with previous findings for another inactivated vaccine.
The scientists said studies will be required to test the candidate vaccine in other age groups, as well as people with pre-existing medical conditions.

Times of India